BPC-157 vs TB-500
BPC-157 is a pentadecapeptide derived from gastric juice with strong localized healing signals, especially in GI and tendon research. TB-500 is a fragment of Thymosin Beta-4 with systemic actin-binding activity driving cell migration, angiogenesis, and broad tissue recovery. Half-lives and delivery profiles are very different; so are their niches.
BPC-157 leads on gut, tendon, and localized soft-tissue research. TB-500 leads on systemic recovery, vascular remodeling, and muscle-tissue research. Practitioners overwhelmingly stack them rather than choose — the mechanisms are complementary, not redundant.
Contender A
BPC-157
Pentadecapeptide from body-protective compound — upregulates VEGFR2, nitric oxide signaling, and growth factor recruitment at injury sites.
- Half-life
- ~30 min plasma, longer tissue residency
- Primary use
- Gut, tendon, and localized soft-tissue research
- Dose range
- 250-500 mcg 1-2x daily
- Cost tier
- $ · Low sourcing cost
Contender B
TB-500
Synthetic fragment of Thymosin Beta-4 — actin-sequestering peptide driving cell migration, angiogenesis, and systemic tissue remodeling.
- Half-life
- ~48 hours
- Primary use
- Systemic recovery and vascular/muscle research
- Dose range
- 2-5 mg weekly (loading: 2x weekly for 4-6 wks)
- Cost tier
- $$ · Moderate sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | BPC-157 | TB-500 | Edge |
|---|---|---|---|
Mechanism class | Growth-factor / nitric-oxide modulator | Actin-sequestering / cell-migration driver | Tie |
Half-life BPC-157 compensates with tissue residency; TB-500 just stays in circulation longer. | ~30 min plasma | ~48 hours | B |
Dosing cadence | Daily (often 2x) | Weekly after load | B |
GI tissue affinity | Strong localized signal | Minimal direct GI data | A |
Tendon / ligament signal | Strong | Moderate | A |
Vascular remodeling | Moderate | Strong | B |
Muscle tissue signal | Moderate | Strong | B |
Research-sourcing cost | Low | Moderate | A |
Injection route options | SubQ, IM, or oral (stable) | SubQ or IM (oral unstable) | A |
Stacks well with the other | Yes | Yes | Tie |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
The healing stack is the most common pairing in the practitioner corpus for a reason — BPC-157 runs the localized repair while TB-500 runs the systemic recovery. Researchers running tendon-injury protocols almost always pair them; running either alone leaves the other mechanism on the table.
The half-life data matters more for dosing cadence than potency. BPC-157's ~30-minute plasma half-life misleads newcomers — tissue residency is much longer, which is why 1-2x daily dosing works despite rapid clearance. TB-500's ~48-hour half-life is why weekly dosing is adequate after the 4-6 week loading phase (2x weekly) saturates tissue.
The oral BPC-157 option is a practitioner-level detail: the molecule is stable enough in acid that oral delivery retains a meaningful fraction of activity, especially for GI-specific research. TB-500 degrades in GI conditions and is effectively injection-only.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Do BPC-157 and TB-500 do the same thing?
+
No. Different mechanism classes. BPC-157 is a growth-factor / nitric-oxide modulator acting primarily at injury sites. TB-500 is an actin-sequestering peptide driving systemic cell migration and angiogenesis. Complementary, not redundant.
Can I take BPC-157 orally?
+
Oral BPC-157 has meaningful bioavailability in acidic conditions — it was originally characterized from gastric juice. Practitioners running GI-specific research protocols often prefer oral delivery. TB-500 is not orally bioavailable.
How long does the healing stack need to run?
+
Protocol audits in our corpus suggest 4-8 week cycles for acute tissue research, with 4 weeks being the minimum useful window. Longer runs (12+ weeks) appear in systemic-recovery protocols.
Are there side effects?
+
Both have clean safety profiles in practitioner reports. Injection-site reactions are the most common. Neither shows hormonal or metabolic disruption at research doses.
Which is stronger?
+
Neither is stronger in a meaningful sense — they do different things. Research questions about localized gut/tendon tissue favor BPC-157. Research questions about systemic recovery or vascular research favor TB-500.
Related Comparisons
GH Axis
Ipamorelin vs CJC-1295
Ipamorelin mimics ghrelin and triggers a GH pulse via the growth hormone secretagogue receptor. CJC-1295 is a GHRH analog that extends and amplifies the natural GH pulse window. They hit different receptors and produce a bigger, cleaner GH pulse when stacked than either does alone.
ReadHealing
GHK-Cu vs Copper Tripeptide
GHK-Cu and 'copper tripeptide' are the same molecule: a glycyl-L-histidyl-L-lysine tripeptide bound to a copper-2 ion. The terminology overlap confuses newcomers. The meaningful research question isn't which molecule — it's topical vs injectable delivery, because the two routes produce very different biological profiles.
ReadLongevity
MOTS-c vs SS-31
MOTS-c is a mitochondrial-derived peptide that signals systemically — it activates AMPK, improves insulin sensitivity, and enhances exercise capacity. SS-31 (elamipretide) is a mitochondrial-targeting peptide that binds cardiolipin on the inner mitochondrial membrane, preserving electron-transport-chain function and reducing oxidative damage. Same organelle, completely different mechanism.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.